Analysis
Science Corporation, the brain-computer interface company founded by former Neuralink president Max Hodak, said on November 17, 2026 that it has raised a $400 million Series D, and a person familiar with the deal told TechCrunch the round values the company at $3.5 billion, as reported by The Next Web.
Science named Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech among the backers and did not name a lead. Science's own announcement says the round brings its total capital raised since its 2021 founding to more than $900 million; its earlier disclosures add up to about $890 million by Pulse's arithmetic, so the company's figure may include money it has not itemized.
What does Science Corp do?
Hodak co-founded Neuralink in 2016 and left to start Science in 2021, per The Next Web. Science's first product, PRIMA, is a wearable and implantable chip for people with age-related macular degeneration. The company calls it the first brain-computer interface to be CE marked to restore form vision, and the implant is now available in Germany. Science says it is pursuing FDA approval through the Humanitarian Device Exemption pathway, a route for rare conditions, and is also testing PRIMA in patients with Stargardt disease. Its second bet is a biohybrid neural interface that integrates engineered neurons with the brain's own circuits, alongside a list of research tools and chips on its site.
“Science named Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech among the backers and did not name a lead.”
The company said the new money will expand PRIMA across Europe, prepare the US launch, grow research, manufacturing and operations, and fund more biohybrid work. Science has not published patient counts, revenue or headcount for PRIMA, and The Next Web gives no US launch date.
How much has Science Corp raised?
- Mar 2026, Series C -- $230 million, total capital of approximately $490 million since founding, with participation from Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT and Quiet Capital, no lead named (Science); valuation of $1.5 billion, per a Bloomberg report cited by The Daily Upside
- Nov 2026, Series D -- $400 million at a reported $3.5 billion, no lead named (The Next Web)
The valuation step is the headline. Against the $1.5 billion reported in March, $3.5 billion is about 2.3 times the prior mark in roughly eight months, a valuation-to-valuation comparison.
On capital, the $400 million Series D is 1.7 times the $230 million Series C. Both valuation figures come from unnamed sources rather than the company.
Who invested in Science Corp?
Khosla Ventures and Y Combinator appear in both the Series C and the Series D lists, so two earlier backers returned in a round reported at more than double the March price. The new names on the list include Tenet Healthcare, the Ackman Oxman Institute, 885 Capital and PLC Neurotech; Science's announcement does not say what role any of them played. Lightspeed, IQT and Quiet Capital, Series C participants, are not named in the Series D announcement, which lists its backers as "among others."
Brain-computer interface market and competitors
The Daily Upside described Science after its March round as the second-most-valuable brain-implant startup behind Elon Musk's Neuralink, and reported that Neuralink had implanted 21 people with chips aimed at spinal cord injuries and is developing a vision chip of its own. Synchron and Precision Neuroscience are the other named rivals. Recent brain-interface rounds for comparison:
- Stairmed -- about $192.5 million in October, backed by Tencent and Alibaba, with a claim of 42 long-term implants (Pulse coverage); Science's round is roughly twice that size
- Bridge Neurotech -- $13.5 million in October for an ultrasound-based interface, per The Next Web
Pulse tracks Neuralink's coverage on its company hub.
The bear case on the $3.5 billion mark
PRIMA is a medical device with one approved market. A Humanitarian Device Exemption is designed for small patient populations, which caps the near-term US addressable market unless Science wins a broader approval later. Reimbursement, surgeon training and the pace of implants in Germany are all undisclosed, so the price rests on a product with no public sales figures. The $3.5 billion figure itself is reported by a person familiar with the deal, not confirmed by Science, and the company's own disclosures stop at the amount raised and the investor list.